Skip to main content
. 2022 Mar 17;29(3):2021–2045. doi: 10.3390/curroncol29030164

Figure A2.

Figure A2

Mixture cure parametric model extrapolations fitted to overall survival and progression-free survival data of brexucabtagene autoleucel (data from ZUMA-2 trial) and BSC (data from meta-analysis). Data derived from ZUMA-2 trial (Brexu-cel) and meta-analysis (BSC). Abbreviations: PFS: progression-free survival; OS: overall survival; ITT: intent-to-treat population; KM: Kaplan–Meier; PS-MCM: partitioned survival mixed cure model.